These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25473895)

  • 1. Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.
    Petti C; Picco G; Martelli ML; Trisolini E; Bucci E; Perera T; Isella C; Medico E
    Oncotarget; 2015 Jan; 6(1):221-33. PubMed ID: 25473895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
    Cepero V; Sierra JR; Corso S; Ghiso E; Casorzo L; Perera T; Comoglio PM; Giordano S
    Cancer Res; 2010 Oct; 70(19):7580-90. PubMed ID: 20841479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
    Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
    Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
    Ji F; Liu X; Wu Y; Fang X; Huang G
    Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.
    Corso S; Ghiso E; Cepero V; Sierra JR; Migliore C; Bertotti A; Trusolino L; Comoglio PM; Giordano S
    Mol Cancer; 2010 May; 9():121. PubMed ID: 20500904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.
    Bachleitner-Hofmann T; Sun MY; Chen CT; Liska D; Zeng Z; Viale A; Olshen AB; Mittlboeck M; Christensen JG; Rosen N; Solit DB; Weiser MR
    Clin Cancer Res; 2011 Jan; 17(1):122-33. PubMed ID: 21208906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
    Prahallad A; Heynen GJ; Germano G; Willems SM; Evers B; Vecchione L; Gambino V; Lieftink C; Beijersbergen RL; Di Nicolantonio F; Bardelli A; Bernards R
    Cell Rep; 2015 Sep; 12(12):1978-85. PubMed ID: 26365186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a novel B-Raf fusion protein related to c-Met drug resistance.
    Dillon R; Nilsson CL; Shi SD; Lee NV; Krastins B; Greig MJ
    J Proteome Res; 2011 Nov; 10(11):5084-94. PubMed ID: 21936566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
    Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
    Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Src impairs the growth of met-addicted gastric tumors.
    Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
    Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.
    Qi J; McTigue MA; Rogers A; Lifshits E; Christensen JG; Jänne PA; Engelman JA
    Cancer Res; 2011 Feb; 71(3):1081-91. PubMed ID: 21266357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.
    Konda JD; Olivero M; Musiani D; Lamba S; Di Renzo MF
    Mol Oncol; 2017 Jun; 11(6):599-611. PubMed ID: 28182330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell lines expressing recombinant transmembrane domain-activated receptor kinases as tools for drug discovery.
    Weber H; Müller D; Müller M; Ortiz A; Birkle M; Umber S; Ketterer C; Siedentopf O; Feger D; Totzke F; Kubbutat M; Schaechtele C; Ballmer-Hofer K; Ehlert JE; Graeser R
    J Biomol Screen; 2014 Dec; 19(10):1350-61. PubMed ID: 25260782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.